Monitor for top-line data from the FOCUS-2 trial (timeline undisclosed). No near-term revenue or regulatory catalyst — solriamfetol is already in earlier-stage ADHD trials, so this is an incremental step. The stock likely sees limited reaction to a dosing announcement alone.
Price Chart
Executive Summary
Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, a 468-patient placebo-controlled study. This is a pipeline-progression event that extends the solriamfetol ADHD program into a younger pediatric population, but no efficacy data or commercial timelines were provided. The event is positive for the pipeline narrative but lacks financial impact or near-term catalyst.
Key Facts
- First patient dosed in FOCUS-2 Phase 3 trial evaluating solriamfetol for children aged 6 to <12 with ADHD
- Trial is randomized, double-blind, placebo-controlled; ~468 patients randomized 1:1:1 to one of two solriamfetol doses or placebo for 6 weeks
- Primary endpoint: change from baseline to week 6 on ADHD-RS-5 total score
- Previously Axsome initiated FOCUS-3 Phase 3 trial of solriamfetol in adolescents (12 to <18) with ADHD
- No financial terms, cash runway implications, or timeline for data readout disclosed in the release
Financial Impact
No financial figures disclosed; pipeline expansion has no near-term revenue impact
Risk Factors
- Phase 3 trial could fail on primary endpoint (ADHD-RS-5), which would impair solriamfetol's ADHD label expansion potential
- Regulatory pathway in pediatric ADHD is untested for solriamfetol; safety and efficacy data required
- Competition from existing ADHD treatments (stimulants, non-stimulants) may limit commercial opportunity even if approved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.28 (−17.88%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.28 (−20.20%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.28 (−20.20%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.28 (−25.79%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.28 (−29.19%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.28 (−29.42%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.28 (−27.85%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.28 (−30.43%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.28 (−30.92%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.28 (−30.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access